Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia
Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need for more suitable MRD markers. Experim...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-04, Vol.12 (8), p.2434-2441 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2441 |
|---|---|
| container_issue | 8 |
| container_start_page | 2434 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | STEINBACH, Daniel SCHRAMM, Alexander ZINTL, Felix GRUHN, Bernd EGGERT, Angelika ONDA, Masanori DAWCZYNSKI, Kristin RUMP, Andreas PASTAN, Ira WITTIG, Susann PFAFFENDORF, Nadine VOIGT, Astrid |
| description | Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used
for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need
for more suitable MRD markers.
Experimental Design: A stepwise approach which combined genome-wide expression profiling, TaqMan low density arrays, and a TaqMan real-time PCR-based
screening was used to identify new markers for the monitoring of MRD in AML. Leukemic cells from 52 children with AML and
145 follow-up samples from 25 patients were analyzed.
Results: Seven genes were identified which are vastly overexpressed in many patients with AML compared with healthy bone marrow: CCL23,
GAGED2, MSLN, SPAG6, and ST18 as well as the previously described markers WT1 and PRAME. The expression of all genes decreased
to normal levels in patients who achieved a continuous complete remission. Elevated levels of at least one gene were found
prior to relapse in 7 out of 10 patients who relapsed.
Conclusions: This set of genes should allow a sensitive and specific monitoring of MRD in AML. Notably, some of these markers could also
serve as therapeutic targets or might be involved in leukemogenesis. MSLN is already used as a target for immunotherapy in
clinical trials in other malignancies. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-2552 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67903001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17151465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-ad176efcb05d997caf20a3439db61e3c8b42b50d855f153eeae399988bc531243</originalsourceid><addsrcrecordid>eNqFkU9vFCEchomxsbX6ETRcNF6mwvBnmGOz1tpkm5pWz4SBH110FlqYqdlvL5Nd06Mn3sPzQnhehN5RckapUJ8p6VRDOGvPVqvbhoimFaJ9gU6oEF3DWile1vyPOUavS_lFCOWU8FfomErJlOL9CdpdOYhT8MGaKaSIk8cG38G0hDt4gogvIULBPmU8bQBfpximlEO8X4jrEMPWjPgWSnBzDV9CAVMAh4i_gwtmysHicztPtbmDMQWH1zD_hm0wb9CRN2OBt4fzFP38evFj9a1Z31xerc7XjRVSTo1xtJPg7UCE6_vOGt8Swzjr3SApMKsG3g6COCWEp4IBGGB93ys1WMFoy9kp-ri_9yGnxxnKpLehWBhHEyHNRcuuJ6yq-S9IOyool6KCYg_anErJ4PVDrhryTlOil3H0Il4v4nUdRxOhl3Fq7_3hgXnYgntuHdaowIcDYIo1o88m2lCeua5jjBJZuU97bhPuN39CBm0rCTlDtZ_tRtNWK13_ztlfTaelpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17151465</pqid></control><display><type>article</type><title>Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>STEINBACH, Daniel ; SCHRAMM, Alexander ; ZINTL, Felix ; GRUHN, Bernd ; EGGERT, Angelika ; ONDA, Masanori ; DAWCZYNSKI, Kristin ; RUMP, Andreas ; PASTAN, Ira ; WITTIG, Susann ; PFAFFENDORF, Nadine ; VOIGT, Astrid</creator><creatorcontrib>STEINBACH, Daniel ; SCHRAMM, Alexander ; ZINTL, Felix ; GRUHN, Bernd ; EGGERT, Angelika ; ONDA, Masanori ; DAWCZYNSKI, Kristin ; RUMP, Andreas ; PASTAN, Ira ; WITTIG, Susann ; PFAFFENDORF, Nadine ; VOIGT, Astrid</creatorcontrib><description>Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used
for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need
for more suitable MRD markers.
Experimental Design: A stepwise approach which combined genome-wide expression profiling, TaqMan low density arrays, and a TaqMan real-time PCR-based
screening was used to identify new markers for the monitoring of MRD in AML. Leukemic cells from 52 children with AML and
145 follow-up samples from 25 patients were analyzed.
Results: Seven genes were identified which are vastly overexpressed in many patients with AML compared with healthy bone marrow: CCL23,
GAGED2, MSLN, SPAG6, and ST18 as well as the previously described markers WT1 and PRAME. The expression of all genes decreased
to normal levels in patients who achieved a continuous complete remission. Elevated levels of at least one gene were found
prior to relapse in 7 out of 10 patients who relapsed.
Conclusions: This set of genes should allow a sensitive and specific monitoring of MRD in AML. Notably, some of these markers could also
serve as therapeutic targets or might be involved in leukemogenesis. MSLN is already used as a target for immunotherapy in
clinical trials in other malignancies.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-2552</identifier><identifier>PMID: 16638849</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Acute Disease ; acute myeloid leukemia ; Adolescent ; Adult ; Antigens, Neoplasm - blood ; Antigens, Neoplasm - genetics ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Bone Marrow - metabolism ; Chemokines, CC - blood ; Chemokines, CC - genetics ; Child ; Child, Preschool ; DNA-Binding Proteins - blood ; DNA-Binding Proteins - genetics ; expression profiling ; Female ; Gene Expression Profiling ; GPI-Linked Proteins ; Hematologic and hematopoietic diseases ; Humans ; Infant ; Infant, Newborn ; Leukemia, Myeloid - blood ; Leukemia, Myeloid - diagnosis ; Leukemia, Myeloid - genetics ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Membrane Glycoproteins - blood ; Membrane Glycoproteins - genetics ; Microtubule Proteins - blood ; Microtubule Proteins - genetics ; minimal residual disease ; Neoplasm, Residual - blood ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - genetics ; Oligonucleotide Array Sequence Analysis - methods ; Pharmacology. Drug treatments ; real-time PCR ; Repressor Proteins ; Reverse Transcriptase Polymerase Chain Reaction ; therapeutic targets ; WT1 Proteins - blood ; WT1 Proteins - genetics</subject><ispartof>Clinical cancer research, 2006-04, Vol.12 (8), p.2434-2441</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-ad176efcb05d997caf20a3439db61e3c8b42b50d855f153eeae399988bc531243</citedby><cites>FETCH-LOGICAL-c566t-ad176efcb05d997caf20a3439db61e3c8b42b50d855f153eeae399988bc531243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17733106$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16638849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEINBACH, Daniel</creatorcontrib><creatorcontrib>SCHRAMM, Alexander</creatorcontrib><creatorcontrib>ZINTL, Felix</creatorcontrib><creatorcontrib>GRUHN, Bernd</creatorcontrib><creatorcontrib>EGGERT, Angelika</creatorcontrib><creatorcontrib>ONDA, Masanori</creatorcontrib><creatorcontrib>DAWCZYNSKI, Kristin</creatorcontrib><creatorcontrib>RUMP, Andreas</creatorcontrib><creatorcontrib>PASTAN, Ira</creatorcontrib><creatorcontrib>WITTIG, Susann</creatorcontrib><creatorcontrib>PFAFFENDORF, Nadine</creatorcontrib><creatorcontrib>VOIGT, Astrid</creatorcontrib><title>Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used
for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need
for more suitable MRD markers.
Experimental Design: A stepwise approach which combined genome-wide expression profiling, TaqMan low density arrays, and a TaqMan real-time PCR-based
screening was used to identify new markers for the monitoring of MRD in AML. Leukemic cells from 52 children with AML and
145 follow-up samples from 25 patients were analyzed.
Results: Seven genes were identified which are vastly overexpressed in many patients with AML compared with healthy bone marrow: CCL23,
GAGED2, MSLN, SPAG6, and ST18 as well as the previously described markers WT1 and PRAME. The expression of all genes decreased
to normal levels in patients who achieved a continuous complete remission. Elevated levels of at least one gene were found
prior to relapse in 7 out of 10 patients who relapsed.
Conclusions: This set of genes should allow a sensitive and specific monitoring of MRD in AML. Notably, some of these markers could also
serve as therapeutic targets or might be involved in leukemogenesis. MSLN is already used as a target for immunotherapy in
clinical trials in other malignancies.</description><subject>Acute Disease</subject><subject>acute myeloid leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Bone Marrow - metabolism</subject><subject>Chemokines, CC - blood</subject><subject>Chemokines, CC - genetics</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>DNA-Binding Proteins - blood</subject><subject>DNA-Binding Proteins - genetics</subject><subject>expression profiling</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>GPI-Linked Proteins</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Leukemia, Myeloid - blood</subject><subject>Leukemia, Myeloid - diagnosis</subject><subject>Leukemia, Myeloid - genetics</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - blood</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Microtubule Proteins - blood</subject><subject>Microtubule Proteins - genetics</subject><subject>minimal residual disease</subject><subject>Neoplasm, Residual - blood</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - genetics</subject><subject>Oligonucleotide Array Sequence Analysis - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>real-time PCR</subject><subject>Repressor Proteins</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>therapeutic targets</subject><subject>WT1 Proteins - blood</subject><subject>WT1 Proteins - genetics</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9vFCEchomxsbX6ETRcNF6mwvBnmGOz1tpkm5pWz4SBH110FlqYqdlvL5Nd06Mn3sPzQnhehN5RckapUJ8p6VRDOGvPVqvbhoimFaJ9gU6oEF3DWile1vyPOUavS_lFCOWU8FfomErJlOL9CdpdOYhT8MGaKaSIk8cG38G0hDt4gogvIULBPmU8bQBfpximlEO8X4jrEMPWjPgWSnBzDV9CAVMAh4i_gwtmysHicztPtbmDMQWH1zD_hm0wb9CRN2OBt4fzFP38evFj9a1Z31xerc7XjRVSTo1xtJPg7UCE6_vOGt8Swzjr3SApMKsG3g6COCWEp4IBGGB93ys1WMFoy9kp-ri_9yGnxxnKpLehWBhHEyHNRcuuJ6yq-S9IOyool6KCYg_anErJ4PVDrhryTlOil3H0Il4v4nUdRxOhl3Fq7_3hgXnYgntuHdaowIcDYIo1o88m2lCeua5jjBJZuU97bhPuN39CBm0rCTlDtZ_tRtNWK13_ztlfTaelpA</recordid><startdate>20060415</startdate><enddate>20060415</enddate><creator>STEINBACH, Daniel</creator><creator>SCHRAMM, Alexander</creator><creator>ZINTL, Felix</creator><creator>GRUHN, Bernd</creator><creator>EGGERT, Angelika</creator><creator>ONDA, Masanori</creator><creator>DAWCZYNSKI, Kristin</creator><creator>RUMP, Andreas</creator><creator>PASTAN, Ira</creator><creator>WITTIG, Susann</creator><creator>PFAFFENDORF, Nadine</creator><creator>VOIGT, Astrid</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20060415</creationdate><title>Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia</title><author>STEINBACH, Daniel ; SCHRAMM, Alexander ; ZINTL, Felix ; GRUHN, Bernd ; EGGERT, Angelika ; ONDA, Masanori ; DAWCZYNSKI, Kristin ; RUMP, Andreas ; PASTAN, Ira ; WITTIG, Susann ; PFAFFENDORF, Nadine ; VOIGT, Astrid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-ad176efcb05d997caf20a3439db61e3c8b42b50d855f153eeae399988bc531243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acute Disease</topic><topic>acute myeloid leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Bone Marrow - metabolism</topic><topic>Chemokines, CC - blood</topic><topic>Chemokines, CC - genetics</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>DNA-Binding Proteins - blood</topic><topic>DNA-Binding Proteins - genetics</topic><topic>expression profiling</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>GPI-Linked Proteins</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Leukemia, Myeloid - blood</topic><topic>Leukemia, Myeloid - diagnosis</topic><topic>Leukemia, Myeloid - genetics</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - blood</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Microtubule Proteins - blood</topic><topic>Microtubule Proteins - genetics</topic><topic>minimal residual disease</topic><topic>Neoplasm, Residual - blood</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - genetics</topic><topic>Oligonucleotide Array Sequence Analysis - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>real-time PCR</topic><topic>Repressor Proteins</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>therapeutic targets</topic><topic>WT1 Proteins - blood</topic><topic>WT1 Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEINBACH, Daniel</creatorcontrib><creatorcontrib>SCHRAMM, Alexander</creatorcontrib><creatorcontrib>ZINTL, Felix</creatorcontrib><creatorcontrib>GRUHN, Bernd</creatorcontrib><creatorcontrib>EGGERT, Angelika</creatorcontrib><creatorcontrib>ONDA, Masanori</creatorcontrib><creatorcontrib>DAWCZYNSKI, Kristin</creatorcontrib><creatorcontrib>RUMP, Andreas</creatorcontrib><creatorcontrib>PASTAN, Ira</creatorcontrib><creatorcontrib>WITTIG, Susann</creatorcontrib><creatorcontrib>PFAFFENDORF, Nadine</creatorcontrib><creatorcontrib>VOIGT, Astrid</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEINBACH, Daniel</au><au>SCHRAMM, Alexander</au><au>ZINTL, Felix</au><au>GRUHN, Bernd</au><au>EGGERT, Angelika</au><au>ONDA, Masanori</au><au>DAWCZYNSKI, Kristin</au><au>RUMP, Andreas</au><au>PASTAN, Ira</au><au>WITTIG, Susann</au><au>PFAFFENDORF, Nadine</au><au>VOIGT, Astrid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-04-15</date><risdate>2006</risdate><volume>12</volume><issue>8</issue><spage>2434</spage><epage>2441</epage><pages>2434-2441</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used
for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need
for more suitable MRD markers.
Experimental Design: A stepwise approach which combined genome-wide expression profiling, TaqMan low density arrays, and a TaqMan real-time PCR-based
screening was used to identify new markers for the monitoring of MRD in AML. Leukemic cells from 52 children with AML and
145 follow-up samples from 25 patients were analyzed.
Results: Seven genes were identified which are vastly overexpressed in many patients with AML compared with healthy bone marrow: CCL23,
GAGED2, MSLN, SPAG6, and ST18 as well as the previously described markers WT1 and PRAME. The expression of all genes decreased
to normal levels in patients who achieved a continuous complete remission. Elevated levels of at least one gene were found
prior to relapse in 7 out of 10 patients who relapsed.
Conclusions: This set of genes should allow a sensitive and specific monitoring of MRD in AML. Notably, some of these markers could also
serve as therapeutic targets or might be involved in leukemogenesis. MSLN is already used as a target for immunotherapy in
clinical trials in other malignancies.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16638849</pmid><doi>10.1158/1078-0432.CCR-05-2552</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-04, Vol.12 (8), p.2434-2441 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67903001 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acute Disease acute myeloid leukemia Adolescent Adult Antigens, Neoplasm - blood Antigens, Neoplasm - genetics Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Bone Marrow - metabolism Chemokines, CC - blood Chemokines, CC - genetics Child Child, Preschool DNA-Binding Proteins - blood DNA-Binding Proteins - genetics expression profiling Female Gene Expression Profiling GPI-Linked Proteins Hematologic and hematopoietic diseases Humans Infant Infant, Newborn Leukemia, Myeloid - blood Leukemia, Myeloid - diagnosis Leukemia, Myeloid - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Membrane Glycoproteins - blood Membrane Glycoproteins - genetics Microtubule Proteins - blood Microtubule Proteins - genetics minimal residual disease Neoplasm, Residual - blood Neoplasm, Residual - diagnosis Neoplasm, Residual - genetics Oligonucleotide Array Sequence Analysis - methods Pharmacology. Drug treatments real-time PCR Repressor Proteins Reverse Transcriptase Polymerase Chain Reaction therapeutic targets WT1 Proteins - blood WT1 Proteins - genetics |
| title | Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A39%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20a%20Set%20of%20Seven%20Genes%20for%20the%20Monitoring%20of%20Minimal%20Residual%20Disease%20in%20Pediatric%20Acute%20Myeloid%20Leukemia&rft.jtitle=Clinical%20cancer%20research&rft.au=STEINBACH,%20Daniel&rft.date=2006-04-15&rft.volume=12&rft.issue=8&rft.spage=2434&rft.epage=2441&rft.pages=2434-2441&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-2552&rft_dat=%3Cproquest_cross%3E17151465%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17151465&rft_id=info:pmid/16638849&rfr_iscdi=true |